Daina Graybosch
Stock Analyst at Leerink Partners
(1.72)
# 2,827
Out of 4,555 analysts
100
Total ratings
39.44%
Success rate
-4.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $3 → $1 | $0.63 | +58.33% | 8 | May 15, 2024 | |
| TSVT 2seventy bio | Upgrades: Outperform | $5 → $18 | $4.36 | +312.84% | 5 | Jan 31, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $74.27 | -47.49% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $5 → $3 | $1.18 | +154.24% | 7 | Feb 24, 2023 | |
| MRK Merck & Co. | Maintains: Outperform | $120 → $122 | $115.41 | +5.71% | 15 | Feb 3, 2023 | |
| IPSC Century Therapeutics | Maintains: Outperform | $20 → $14 | $1.54 | +809.09% | 4 | Jan 6, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $3.45 | +189.86% | 6 | Jan 6, 2023 | |
| AFMD Affimed | Maintains: Outperform | $100 → $60 | $3.92 | +1,430.61% | 7 | Dec 12, 2022 | |
| IPHA Innate Pharma | Maintains: Outperform | $10 → $9 | $2.25 | +300.02% | 9 | Nov 15, 2022 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $40 → $38 | $16.31 | +132.99% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $28 | $1.70 | +1,547.06% | 5 | Sep 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $5.63 | +42.22% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $100.53 | +122.82% | 13 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $5.91 | +407.61% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $59 | $15.56 | +279.18% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $2.13 | +698.12% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.98 | +354.55% | 2 | Feb 25, 2022 |
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.63
Upside: +58.33%
2seventy bio
Jan 31, 2024
Upgrades: Outperform
Price Target: $5 → $18
Current: $4.36
Upside: +312.84%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $74.27
Upside: -47.49%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $5 → $3
Current: $1.18
Upside: +154.24%
Merck & Co.
Feb 3, 2023
Maintains: Outperform
Price Target: $120 → $122
Current: $115.41
Upside: +5.71%
Century Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $1.54
Upside: +809.09%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $3.45
Upside: +189.86%
Affimed
Dec 12, 2022
Maintains: Outperform
Price Target: $100 → $60
Current: $3.92
Upside: +1,430.61%
Innate Pharma
Nov 15, 2022
Maintains: Outperform
Price Target: $10 → $9
Current: $2.25
Upside: +300.02%
Arcus Biosciences
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $16.31
Upside: +132.99%
Sep 27, 2022
Maintains: Outperform
Price Target: $25 → $28
Current: $1.70
Upside: +1,547.06%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $5.63
Upside: +42.22%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $100.53
Upside: +122.82%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $5.91
Upside: +407.61%
May 13, 2022
Maintains: Outperform
Price Target: $60 → $59
Current: $15.56
Upside: +279.18%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $2.13
Upside: +698.12%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.98
Upside: +354.55%